Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in adults with previously treated EGFR ex20ins+ metastatic non-small cell lung cancer (mNSCLC) in the EXCLAIM extension...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia Campelo, Maria Rosario, Zhou, Caicun, Ramalingam, Suresh S., Lin, Huamao M., Kim, Tae Min, Riely, Gregory J., Mekhail, Tarek, Nguyen, Danny, Goodman, Erin, Mehta, Minal, Popat, Sanjay, Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821270/
https://www.ncbi.nlm.nih.gov/pubmed/36614913
http://dx.doi.org/10.3390/jcm12010112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821270/
https://www.ncbi.nlm.nih.gov/pubmed/36614913
http://dx.doi.org/10.3390/jcm12010112

Ejemplares similares